1. Medtech Insight
  2. >>Policy & Regulation

Correction Means Lower Medicare Outpatient Rates Than Expected For Stereotactic Radiosurgery

A correction notice issued by CMS to fix technical errors in the 2014 draft hospital outpatient prospective payment system cut its payment proposal for stereotactic radiosurgery by about $3,000 compared to a proposed rule issued in July.

A fix to some technical errors has resulted in an approximately $3,000 reduction in the outpatient reimbursement rates that CMS is proposing for stereotactic radiosurgery in 2014. But even with the adjustment, stereotactic radiosurgery outpatient rates will still see an increase compared with current 2013 payments.

The agency issued a correction notice on Sept. 4 to fix errors it had identified in its 2014...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

HeartFlow Takes Another Crack At Public Markets With $100M IPO Filing

 
• By Marion Webb

AI heart imaging company HeartFlow filed for a $100m IPO after scrapping its 2022 SPAC plans. It remains unprofitable but is betting on FDA clearances, Medicare coverage and a demand for AI-powered diagnostics to win over investors.

FDA Document Request Denied As Case Against SurModics Merger Intensifies

 
• By Elizabeth Orr

A federal court in Illinois ruled against SurModics and BC Holdings' request for FDA documents to support a proposed merger. The FTC has challenged the merger, claiming it threatens competition in hydrophilic device coatings. The ruling may indicate the FTC is likely to succeed.

Abbott Lowers Outlook But Headwinds Are Temporary

 
• By Natasha Barrow

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.